preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Lactobacillus
inflammatory bowel disease
Lactobacillus has meaningful literature visibility in inflammatory bowel disease, but the current evidence mix suggests a substantial risk of overclaiming.
Lactobacillus shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
lactobacillus
Credibility score
39
Human translation
1/5
Reproducibility
5/5
Novelty
2/5
Actionability
2/5
Credibility 39Human translation 1/5Reproducibility 5/5Novelty 2/5Actionability 2/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
- review density exceeds central evidence depth
Internal review flags
2 flagsreview_heavy
Review literature is very dense relative to primary central evidence.
Primary central evidence
6 papersEffect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial.
2019The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.
2019Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Colon-Targeted Adhesive Hydrogel Microsphere for Regulation of Gut Immunity and Flora.
2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera.
2022Frontiers in immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism.
2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Higher alpha diversity and Lactobacillus blooms are associated with better engraftment after fecal microbiota transplant in inflammatory bowel disease.
2024Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
16 papersCARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands.
2016Nature medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology.
2019Cell reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fecal Microbiota Transplantation (FMT) Alleviates Experimental Colitis in Mice by Gut Microbiota Regulation.
2020Journal of microbiology and biotechnology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats.
2021Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Icariin Inhibits Intestinal Inflammation of DSS-Induced Colitis Mice Through Modulating Intestinal Flora Abundance and Modulating p-p65/p65 Molecule.
2021The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota metabolite indole-3-acetic acid maintains intestinal epithelial homeostasis through mucin sulfation.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dehydroevodiamine Alleviates Ulcerative Colitis by Inhibiting the PI3K/AKT/NF-κB Signaling Pathway via Targeting AKT1 and Regulating Gut Microbes and Serum Metabolism.
2024Molecules (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis.
2024Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbial and metabolomics profiles reveal the potential mechanism of fecal microbiota transplantation in modulating the progression of colitis-associated colorectal cancer in mice.
2024Journal of translational medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The inflammatory bowel disease and gut microbiome are restored by employing metformin-loaded alginate-shelled microcapsules.
2025Journal of controlled release : official journal of the Controlled Release Society
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lactobacillus rhamnosus GG induces STING-dependent IL-10 in intestinal monocytes and alleviates inflammatory colitis in mice.
2025The Journal of clinical investigation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota-derived tryptophan metabolites regulated by Wuji Wan to attenuate colitis through AhR signaling activation.
2025Acta pharmaceutica Sinica. B
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Probiotic Delivery for Editing of the Gut Microbiota to Mitigate Colitis and Maintain Hepatic Homeostasis Via Gut-Liver Axis.
2025ACS nano
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbial Nordihydroguaiaretic acid suppresses macrophage pyroptosis to regulate epithelial homeostasis and inflammation.
2025Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
A Microalgae-Probiotic-Nanozyme Robot for Alleviating Intestinal Inflammation and Microbiota Dysbiosis.
2025Advanced materials (Deerfield Beach, Fla.)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Periodontitis salivary microbiota exacerbates colitis by CXCL3 derived from gut microbiota-induced macrophages.
2025Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
22 papersProbiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.
2008British journal of clinical pharmacology
Relevant review or meta-analysis for the signal-disease area.
Probiotics.
2009Indian journal of medical microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and pediatric disease.
2011Digestive diseases (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
Probiotics: an update.
2015Jornal de pediatria
Relevant review or meta-analysis for the signal-disease area.
Probiotics and Their Use in Inflammatory Bowel Disease.
2018Alternative therapies in health and medicine
Relevant review or meta-analysis for the signal-disease area.
Efficacy of Lactobacillus plantarum in prevention of inflammatory bowel disease.
2018Toxicology reports
Relevant review or meta-analysis for the signal-disease area.
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
2018PloS one
Relevant review or meta-analysis for the signal-disease area.
Thirty Years of Lactobacillus rhamnosus GG: A Review.
2019Journal of clinical gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.
2019United European gastroenterology journal
Relevant review or meta-analysis for the signal-disease area.
Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
2020Current clinical pharmacology
Relevant review or meta-analysis for the signal-disease area.
The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease.
2020Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis.
2021European journal of nutrition
Relevant review or meta-analysis for the signal-disease area.
Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis.
2021International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
2021The Cochrane database of systematic reviews
Relevant review or meta-analysis for the signal-disease area.
Adrenomedullin: Not Just Another Gastrointestinal Peptide.
2022Biomolecules
Relevant review or meta-analysis for the signal-disease area.
Lactobacillus and intestinal diseases: Mechanisms of action and clinical applications.
2022Microbiological research
Relevant review or meta-analysis for the signal-disease area.
Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.
2023World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms.
2023Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?
2024Advances in therapy
Relevant review or meta-analysis for the signal-disease area.
Exploration of the Muribaculaceae Family in the Gut Microbiota: Diversity, Metabolism, and Function.
2024Nutrients
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota mediated T cells regulation and autoimmune diseases.
2024Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Microbiota and inflammatory bowel disease: the dual effect mechanism of polysaccharide therapy.
2025Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.